Differential Regulation of VEGF, Cadherin, Angiopietin 2 by Trigger Oocyte Maturation With GnRHa vs hCG in Donors
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Introduction OHSS still remains a complication of assisted reproduction treatments. hCG administration to trigger final oocyte maturation will release vascular mediators, being VEGF and other proteins such as VE-Cadherin or Angiopoietin- 2. It has been shown that replacing hCG by GnRH agonists will induce a very short endogenous LH peak, potent enough to induce final oocyte maturation but no OHSS will develop. The investigators examined VEGF, VE-Cadherin and Angiopoietin-2 modulation by hCG as well as GnRH agonists in oocyte donors undergoing controlled ovarian stimulation.
| Condition |
|---|
|
Messurement Levels of VEGF |
| Study Type: | Observational |
| Study Design: | Observational Model: Cohort Time Perspective: Prospective |
| Official Title: | Differential Regulation of VEGF, Cadherin and Angiopietin 2 by Trigger Oocyte Maturation With GnRHa vs hCG in Donors: Try to Explain the Lower OHSS Incidence |
- well Levels of VEGF, sVE-Cadherin an Angiopietin 2 were determined by ELISA in serum and in follicular fluid. [ Time Frame: 1 year ] [ Designated as safety issue: Yes ]
Biospecimen Retention: Samples With DNA
follicular fluid
| Enrollment: | 60 |
| Study Start Date: | June 2008 |
| Study Completion Date: | March 2009 |
| Primary Completion Date: | February 2009 (Final data collection date for primary outcome measure) |
| Groups/Cohorts |
|---|
|
Group1
Protocol with antagonist and hCG to trigger oocyte maturation
|
|
Group 2
Protocol with antagonist and 0,2 mg triptorelin to trigger oocyte maturation
|
|
Group 3
Long Protocol and hCG to trigger oocyte maturation
|
Detailed Description:
Material and Methods Between June and December of 2008 we evaluated 90 egg donors. They underwent COH with 150 IU rFSH as starting dose, we separated them in 3 groups (n:30 each): Groups 1 and 2 received a 0.25mg daily dose of GnRH antagonist when a follicle 14mm in diameter was observed. hCG 250g was given to group 1 while group 2 received triptorelin 0.2mg when leading two follicles were 17mm. Group 3 was stimulated with standard long protocol, hCG was given following similar criteria.
Blood was collected the day of hCG/aGnRH administration as well as the day of egg retrieval, and follicular fluid from the first two mature follicles was also frozen. We collected granulosa cells (GC) of 10 patients of each group as well Levels of VEGF, sVE-Cadherin an Angiopietin 2 were determined by ELISA in serum and in follicular fluid.
Results were analyzed via ANOVA.Data are expressed as mean± SEM. A significant difference was defined as p< 0.05.
Eligibility| Ages Eligible for Study: | 18 Years to 34 Years |
| Genders Eligible for Study: | Female |
| Accepts Healthy Volunteers: | Yes |
| Sampling Method: | Non-Probability Sample |
oocyte Donors
Inclusion Criteria:
- Donors
Exclusion Criteria:
- Important diseases
Contacts and Locations More Information
No publications provided
| Responsible Party: | MCerrillo, IVI Madrid |
| ClinicalTrials.gov Identifier: | NCT00848185 History of Changes |
| Other Study ID Numbers: | IVIMAD-MC-10-2008-01 |
| Study First Received: | February 19, 2009 |
| Last Updated: | September 16, 2009 |
| Health Authority: | Spain: Comité Ético de Investigación Clínica |
Keywords provided by Instituto Valenciano de Infertilidad, Spain:
|
VEGF Trigger OHSS |
ClinicalTrials.gov processed this record on May 23, 2013